• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.

作者信息

Kalac Matko, Lue Jennifer K, Lichtenstein Emily, Turenne Ithamar, Rojas Celeste, Amengual Jennifer E, Sawas Ahmed, Deng Changchun, Mapara Markus Y, Connors Joseph M, Kuruvilla John, O'Connor Owen A

机构信息

Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA.

Department of Hematology and Oncology, Columbia University Medical Center, New York, NY, USA.

出版信息

Br J Haematol. 2018 Mar;180(5):757-760. doi: 10.1111/bjh.14449. Epub 2016 Dec 16.

DOI:10.1111/bjh.14449
PMID:27984643
Abstract
摘要

相似文献

1
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.在化疗难治性霍奇金淋巴瘤患者中，维布妥昔单抗和苯达莫司汀产生了高完全缓解率。
Br J Haematol. 2018 Mar;180(5):757-760. doi: 10.1111/bjh.14449. Epub 2016 Dec 16.
2
Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.苯达莫司汀可作为复发的、对本妥昔单抗难治的霍奇金淋巴瘤进行异基因移植的桥梁。
Br J Haematol. 2017 Dec;179(5):841-843. doi: 10.1111/bjh.14257. Epub 2016 Jul 22.
3
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.苯达莫司汀对复发/难治性 Brentuximab vedotin 的霍奇金淋巴瘤患者的疗效。
Br J Haematol. 2013 Dec;163(5):681-3. doi: 10.1111/bjh.12548. Epub 2013 Aug 30.
4
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.复发或难治性霍奇金淋巴瘤患者接受本妥昔单抗治疗失败后单药苯达莫司汀的安全性和有效性：27例患者的经验
Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):404-8. doi: 10.1016/j.clml.2015.02.023. Epub 2015 Mar 5.
5
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.欧洲药品管理局对用于治疗复发或难治性CD30+霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤成年患者的本妥昔单抗（安适利）的审评：人用药品委员会科学评估总结
Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.
6
Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.苯达莫司汀作为复发/难治性霍奇金淋巴瘤患者异基因移植的桥梁，这些患者在自体外周血干细胞移植后接受挽救性本妥昔单抗治疗失败。
Leuk Lymphoma. 2017 Nov;58(11):2745-2747. doi: 10.1080/10428194.2017.1307362. Epub 2017 Mar 28.
7
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.本妥昔单抗维达汀联合苯达莫司汀治疗难治性或复发性霍奇金淋巴瘤。一项回顾性真实世界研究。
Eur J Haematol. 2020 Jun;104(6):581-587. doi: 10.1111/ejh.13400. Epub 2020 Mar 13.
8
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.在未经选择的 CD30 阳性侵袭性淋巴瘤患者中，采用 Brentuximab Vedotin 联合苯达莫司汀治疗。
Eur J Haematol. 2020 Mar;104(3):251-258. doi: 10.1111/ejh.13368. Epub 2020 Jan 10.
9
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.在复发难治性经典型霍奇金淋巴瘤的儿童、青少年和年轻成人中，将苯达莫司汀添加到维布妥昔单抗中可提高完全代谢缓解率：一项回顾性单中心研究系列。
Br J Haematol. 2021 Feb;192(3):e84-e87. doi: 10.1111/bjh.17274. Epub 2021 Jan 10.
10
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.复发/难治性霍奇金淋巴瘤自体移植前，以本妥昔单抗作为二线治疗的多中心II期试验结果。
Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-2140. doi: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26.

引用本文的文献

1
Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study.对于年龄≤60岁的经典型霍奇金淋巴瘤患者，在接受两个周期的阿霉素-博来霉素-长春花碱-达卡巴嗪治疗后未获得完全代谢缓解时，苯达莫司汀强化联合 Brentuximab vedotin 作为早期挽救治疗：一项回顾性多中心研究的长期疗效结果。
Br J Haematol. 2025 May;206(5):1502-1507. doi: 10.1111/bjh.20053. Epub 2025 Apr 2.
2
Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma.填补空白：复发/难治性霍奇金淋巴瘤的免疫治疗武器库
J Clin Med. 2022 Nov 6;11(21):6574. doi: 10.3390/jcm11216574.
3
Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin's Lymphoma: So Many Options, How to Choose?复发/难治性经典型霍奇金淋巴瘤初始治疗的新型挽救治疗方案：选择众多，如何抉择？
Cancers (Basel). 2022 Jul 20;14(14):3526. doi: 10.3390/cancers14143526.
4
Salvage Therapy for Hodgkin's Lymphoma: A Review of Current Regimens and Outcomes.霍奇金淋巴瘤的挽救治疗：当前治疗方案及结果综述
J Blood Med. 2020 Oct 27;11:389-403. doi: 10.2147/JBM.S250581. eCollection 2020.
5
Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma.Brentuximab vedotin 序贯泊马度胺超剂量治疗难治或复发霍奇金淋巴瘤。
Blood Adv. 2019 May 14;3(9):1546-1552. doi: 10.1182/bloodadvances.2019000123.
6
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.贝林妥欧单抗联合吉西他滨治疗儿童和青年复发或难治性霍奇金淋巴瘤患者（AHOD1221）：一项儿童肿瘤学组多中心单臂 1-2 期试验。
Lancet Oncol. 2018 Sep;19(9):1229-1238. doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 16.
7
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.本妥昔单抗维迪西妥单抗联合苯达莫司汀：复发或难治性霍奇金淋巴瘤的高效一线挽救治疗方案。
Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27.
8
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.复发/难治性霍奇金淋巴瘤的病理生理学与治疗进展，重点关注靶向治疗和移植策略
Blood Lymphat Cancer. 2017;7:37-52. doi: 10.2147/BLCTT.S105458. Epub 2017 May 9.